Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

BerGenBio Announces Initiation of Phase 2a in First Line Non-Small Lung Cancer Patients with a STK11 mutation

BerGenBio receives positive recommendation from independent Data and Safety Monitoring Board to proceed without study modification     Bergen, Norway, March 20, 2024, – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today it has initiated the Phase 2a portion of the BGBC016 clinical study of its selective AXL inhibitor bemcentinib in combination with standard of care therapy in first-line Non Small Cell Lung Cancer (NSCLC) patients harboring a STK11 mutation (

Resolutions by Stora Enso Oyj’s Annual General Meeting and the organising meeting of the Board of Directors

STORA ENSO OYJ STOCK EXCHANGE RELEASE 20 March 2024 at 18:15 EETStora Enso Oyj’s ("Stora Enso" or the "Company") Annual General Meeting (the "AGM") was held on 20 March 2024 at Marina Congress Center in Helsinki, Finland. The AGM adopted the accounts for 2023, adopted the remuneration report for 2023 through an advisory resolution and granted the Company’s Board of Directors and Chief Executive Officer discharge from liability for the period. Resolution on the use of the profit shown on the balance sheet and the payment of dividendThe AGM resolved, in accordance with the proposal by

#24-25 Kiliaro Group AB approved for listing at NGM

Nordic Growth Market NGM AB (“NGM“) has, as previously announced, decided to list the shares in Kiliaro Group AB at NGM. The first day of trading has been set to March 22, 2024. The shares in Kiliaro Group AB have previously been listed at Nasdaq First North Growth Market.Information regarding the affected instrument:Listing name: Kiliaro GroupExchange symbol: KILIISIN-code: SE0016275333CFI-code: ESVUFRFISN-code: KILIARO/SHInstrument-ID: EBVNTick size table/liquidity band: 2Number of issued shares: 29 301 703First day of trading: 2024-03-22Market-ID: NSMESegment-ID:

Foundry is launching in Early Access on May 2nd

Players will be able to experience the 3D voxel-based factory builder soonStockholm and Vancouver, March 20 - Today, Paradox Interactive and Channel 3 Entertainment are thrilled to announce that Foundry will be launching in Early Access on Steam on May 2nd. Foundry, the procedurally-generated voxel factory-building and automation sandbox, already garnered 100,000 players during its alpha phase on Itch.io and its demo on Steam Next Fest in October 2023. You can check Foundry's new trailer here . Foundry is a first-person, factory-building

#24-101 Listing of Derivatives at NGM

Information about various derivatives that will be listed at NGM.For more details, see attached file. For further information concerning this NGM notice please contact NGM Listing department on listings@ngm.se. Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a complete platform for companies

Aker ASA: Key information relating to proposed cash dividend

Aker ASA's Board of Directors has decided to propose to the Annual General Meeting on 17 April 2024, to pay an ordinary dividend to Aker's shareholders of NOK 15.50 per share for the fiscal year 2023, and that the Annual General Meeting authorizes the Board to adopt an additional dividend during 2024 based on the 2023 annual accounts. Dividend amount: NOK 15.50 per shareDeclared currency: NOKApproval date: 17 April 2024Last day including right: 17 April 2024Ex-date: 18 April 2024Record Date: 19 April 2024Payment date: On or about 29 April 2024 -ENDS-  For further

Bulletin from AGM in Rottneros

Among others, the following resolutions were passed at the Annual General Meeting (the “AGM”) of Rottneros AB (publ) (“Rottneros” or the “Company”) held today, on 20 March 2024. Adoption of income statement and balance sheet for the financial year 2023 and discharge from liability The AGM resolved to adopt the income statement and the consolidated income statement for the financial year 2023 as well as the balance sheet and consolidated balance sheet as of 31 December 2023, as set out in the annual report. The members of the board of directors and the managing director were discharged

Resqunit enters conditional agreement on purchase of IPR and financing to enable continued development of existing operations

Resqunit AB (publ) ("Resqunit" or the "Company") has today announced its entry into a conditional agreement for the acquisition of intellectual property rights and a capital injection from Bio Vitos Norge AS ("Bio Vitos" and the "Acquisition" respectively). The intellectual property rights (the “IPR”) acquired primarily encompass business assets related to the distribution and sale of health products containing Omega 3 (the "New Business"). The board of directors of the Company has evaluated the New Business as a significant opportunity to enhance the Company's potential for achieving

YA Holding obtains the bondholders’ approval regarding proposed refinancing arrangement and for changes to the terms of its existing bond loan

YA Holding AB (publ) (the “Company”) announces that the written procedure initiated on 1 March 2024 (the “Written Procedure”) regarding, inter alia, the restructuring of the capital structure and certain liabilities of the Company (the “Refinancing Arrangement”) and certain amendments to the terms and conditions (“T&C Amendments”) of the Company’s senior secured sustainability-linked corporate bonds with ISIN SE0016831150 (the “Bonds”), has been concluded. A sufficient number of votes have been obtained to achieve quorum and a sufficient majority of the participating bondholders have

Decisions of the constitutive meeting of Fondia's Board of Directors

Fondia Plc Company release20.3.2024 at 5.00 p.m. The Board of Directors elected today at the Annual General Meeting, held an organizational meeting immediately after the conclusion of the Annual General Meeting. Timo Lappi was elected as Chairperson of the Board. The Board decided not to establish any committees.At its meeting, the Board assessed the independence of its members in accordance with the Finnish Corporate Governance Code for listed companies. The Board concluded that of the members Charlotte Darth, Juha Sarsama, Katariina Lindholm and Sami Honkonen are independent of

Conversion of Nightingale Health Plc’s EMP shares to Series B shares

Company release, 20 March 2024 at 5:00 p.m. (EET) The Board of Directors of Nightingale Health Plc (“Nightingale Health”) has in its meeting on 18 December 2023, approved request of shareholders to convert 79,765 EMP shares to Series B shares in accordance with Article 5 in the Articles of Association. As a result of conversion of shares, the number of the Nightingale Health’s Series A shares is 20,585,924 and Series B shares is 39,233,735 and EMP shares is 1,098,800. The conversion does not affect the total amount of shares which is 60,918,459. The number of votes of Nightingale

ChemoTech signs new agreement with a private hospital & medical college

Scandinavian ChemoTech’s Indian operation has today signed a new contract for a new installation of the IQwave™ and TSE (Tumour Specific Electroporation™) device with Chhatrapati Shivaji Subharti Hospital (CSSH) & Medical College.   The installation consists of a training and an integration phase. The initial non-commercial phase is limited to one month and will then, if approved by the hospital administration, enter the commercial phase. If approved the signed agreement will amount to a minimum consumption of kits equal to EUR 70,000 per year.   The Chhatrapati Shivaji Subharti

ChemoTech adapts its strategy and short-term targets for Human Care

After not achieving its latest adjusted short-term targets of installed units in India, the company is shifting its strategy to favor long-term clinical and commercial targets.   Last year, fueled by the optimism of potential clients, our recent success in protocol changes at our clinical trials at AIIMS, and the vast market potential in India, we set forth ambitious targets for both public and private hospitals. Throughout this process, it has become evident that our optimal path to achieving the substantial volumes we aspire to in India lies in adapting our strategy for the upcoming

Startup Moldova Summit 2024: Driving Innovation and Growth

Chisinau, March 20, 2024 - The Startup Moldova Summit 2024 , held on March 14, 2024, emerged as a critical point in Moldova's technological landscape, hosting over 500 attendees and 30 venture capitalists and angel investors. Facilitating more than 350 networking sessions with startups, the summit provided an interactive forum for collaboration, knowledge exchange, and networking. Esteemed figures, including President Maia Sandu and

NOTICE TO ATTEND THE ANNUAL GENERAL MEETING IN SILEON AB (PUBL)

The shareholders of Sileon AB (publ) (the “Company” or “Sileon”), reg. no. 556584-5889, with its registered office in Stockholm, are hereby invited to the Annual General Meeting on Tuesday 23 April 2024 at 2:00 PM CEST, at the Company’s premises in Münchenbryggeriet, Söder Mälarstrand 65, floor 5, in Stockholm.Right to participate in the Annual General Meeting and notice of participation Notice of participation A shareholder who wishes to participate in the Annual General Meeting in person or represented by a proxy must (i) be recorded as a shareholder in the share register maintained

Read original

Swedavia’s Annual and Sustainability Report 2023: Continued recovery strengthens confidence in the future

As of 20 March, Swedavia's Annual and Sustainability Report for 2023 will be available on the company's website. In 2023, the recovery from the low traffic volumes of previous years continued, with new airlines coming and old ones returning to the company’s airports, with most routes and destinations restored. During the year, Swedavia continued to take new steps in the transition to fossil-free aviation, and in December, Göteborg Landvetter Airport and Malmö Airport received the highest level of certification according to the Airport Carbon Accreditation - the international industry standard

Kemira Oyj: Members of the Board Committees

Kemira Oyj, Stock Exchange Release, March 20, 2024 at 4.15 pm (EET)Kemira Oyj: Members of the Board Committees   The Board of Directors of Kemira Oyj elected members among themselves for the Personnel and Remuneration Committee and Audit Committee at its meeting today.The Board’s Personnel and Remuneration Committee members are Tina Sejersgård Fanø, Timo Lappalainen, Annika Paasikivi and Mikael Staffas. The Personnel and Remuneration Committee is chaired by Annika Paasikivi. The Board’s Audit Committee members are Werner Fuhrmann, Timo Lappalainen, Fernanda Lopes Larsen and

Finland, the happiest country – is this one of the reasons?

Finland was dubbed the world’s happiest nation for the seventh consecutive year in the annual World Happiness Report 2024. The happiest nation might also boast the most contented employees. Here’s why:Finland is renowned for its citizens’ well-being, ice swimming, sauna culture, Northern Lights, and other unique Nordic experiences the country offers. It’s also celebrated for maintaining one of the most functional work-life balances globally. Even as the work-life balance is well-working in Finland, there is discussion about adopting shorter workweeks. Could this afford more time to spend

Aker Solutions ASA: Sale of own shares for Employee Share Purchase Program

March 20, 2024 – Aker Solutions ASA (“Aker Solutions”) has sold own shares in connection with the company’s employee share purchase program for 2024.The program entitles employees of the company in Norway to purchase shares of Aker Solutions for an amount up to NOK 60,000. Shares are offered at a maximum discount of NOK 7,500 (discount not to exceed 25 percent of the subscription amount) per participant for the entire 2024 program.  Allocation of shares to participants is quarterly; in March, June, September and December 2024. In addition, participants who remain employed and have not

Revolutionary Evotip Workflow Enables Unprecedented Proteomic Analysis

FOR IMMEDIATE RELEASE   Proteomics and diagnostics    Media Contact Information:Christian Ravnsborg  +45 26 33 20 21  cr@evosep.com   Making clinical proteomics 100x more robust and 10x faster    [Odense, March 20th, 2024] – Evosep, a leading provider of sample preparation and separation solutions for mass spectrometry-based proteomics, is thrilled to announce the publication of a groundbreaking study in Nature Communications highlighting the capabilities of its innovative Evotip technology.

Attendo releases Annual Report and Sustainability Report for 2023

Attendo's Annual Report and Sustainability Report for 2023 is now available for download from Attendo's website. The report describes the development in 2023, which was characterized by clear improvements in both operations and financial results, driven by the transition work in Finland. During the year, Attendo also took important steps to develop its sustainability work.The annual report presents Attendo's updated strategic framework, which is based on three strategic objectives: to be the preferred choice for customers and relatives, employees and clients; to be a natural and fundamental

There are no items matching the current filter
There are no more items matching the current filter
Back to top